Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Description

This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.

Conditions

Pancreatic Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.

Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Morgantown

Shailendra Singh, Morgantown, West Virginia, United States, 26508

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of pancreatic cancer based on clinical, radiological, or pathological assessment;
  • * Referred for abdominal and/or back pain due to pancreatic cancer;
  • * No prior history of RFA;
  • * Cancer pain unresponsive to the WHO 3-step analgesic ladder;
  • * Willingness to consent to participate in the study.
  • * Patients who are not willing to give informed consent or agree to participate in the study
  • * Surgically resectable pancreatic cancer;
  • * Abdominal pain with etiology other than pancreatic malignancy;
  • * Evidence of concurrent infection;
  • * Patients with irreversible coagulopathy international normalized ratio \>1.5 or platelet count \<50,000/mm3),
  • * Patients with a preliminary diagnosis of adenocarcinoma are not possible established with intraprocedural at EUS-guided FNA.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

West Virginia University,

Shailendra Singh, MD, PRINCIPAL_INVESTIGATOR, West Virginia University

Study Record Dates

2025-12